Navigation Links
A drug used to treat HIV might defuse deadly staph infections
Date:12/14/2012

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year. Their study is published online this week in Nature.

"What are the chances that a drug for HIV could possibly treat a virulent Staph infection?" asks Victor J. Torres, PhD, assistant professor of microbiology, and senior author of the study. "These findings are the result of a fantastic collaboration that we hope will result in significant clinical benefit." Staph causes toxic shock syndrome, pneumonia, and food poisoning, among other illnesses, and is becoming increasingly resistant to antibiotics.

The discovery arose from a serendipitous finding that was a part of a collaborative study between Dr. Torres, a bacteriologist, and immunologist Derya Unutmaz, MD, associate professor of microbiology and pathology and medicine, whose laboratories are adjacent to each other.

They focused on a receptor called CCR5 that dots the surface of immune T cells, macrophages, and dendritic cells. Sixteen years ago, researchers at NYU School of Medicine discovered that CCR5 is the receptor HIV uses to gain entry into T cells in order to replicate, spread, and cause an infection that can progress into AIDS.

That same receptor has now been found to be critical to the ability of certain strains of Staph to specifically target and kill cells with CCR5, which orchestrate an immune response against the bacteria. The scientists discovered that one of the toxins the bacterium releases, called LukED, latches on to CCR5 and subsequently punches holes through the membrane of immune cells, causing them to rapidly die. The LukED toxin belongs to a family of proteins called leukotoxins, encoded and produced by Staph to fight off the immune system's defenses.

This discovery was made
'/>"/>

Contact: Christopher Rucas
Christopher.Rucas@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Lethal stings from the Australian box jellyfish could be treated with zinc
2. Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
3. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
4. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
5. ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments
6. Protein injection points to muscular dystrophy treatment
7. Possible new treatment for Ewing sarcoma
8. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
9. Notre Dame research could improve sustainability and cost effectiveness of wastewater treatment
10. Second most common infection in the US proving harder to treat with current antibiotics
11. Hormone combination effective and safe for treating obesity in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Infection with West Nile virus (WNV) causes no symptoms ... encephalitis. What determines the outcome of infection with WNV in ... and colleagues, at the Blood Systems Research Institute, San Francisco, ... (immune cells that suppress the function of other immune cells) ...
... New Orleans, LA Dr. John England, Professor and ... analyzed research findings and was responsible for the quality and ... resulting in new guidelines for treating Lou Gehrig,s disease, or ... the October 13, 2009 issue of Neurology , the ...
... target to stem biodiversity loss by next year, according to ... to biodiversity science. The goal was agreed at ... Biological Diversity in April 2003. Some 123 world ministers ... current rate of biodiversity loss at the local, national and ...
Cached Biology News:LSUHSC's England plays key role in developing new ALS treatment guidelines 2World will miss 2010 target to stem biodiversity loss, experts say 2World will miss 2010 target to stem biodiversity loss, experts say 3World will miss 2010 target to stem biodiversity loss, experts say 4World will miss 2010 target to stem biodiversity loss, experts say 5World will miss 2010 target to stem biodiversity loss, experts say 6
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , SAN FRANCISCO , Feb. ... ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... shares of common stock, and warrants to purchase 4.2 million shares ... , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with ...
... ... for Manufacture and Testing of Drug Products Imported to the European Union. ... Toronto, Ontario (PRWEB) ... to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. ...
... , FORT LAUDERDALE, Fla. , ... published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated ... and no late stent thrombosis at one year in ... percutaneous coronary intervention (PCI) and implantation of the company,s ...
Cached Biology Technology:Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 2Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 3OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 3
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: